Ionis and Otsuka score EU nod for DAWNZERA, offering new hope for rare HAE patients
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The product delivers 100 percent of the Recommended Dietary Allowance (RDA) of three essential nutrients—Biotin, Vitamin C and Zinc
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
Subscribe To Our Newsletter & Stay Updated